ANDA (Abbreviated New Drug Application) is a regulatory submission that pharmaceutical companies submit to the Food and Drug Administration (FDA) to seek approval to sell generic drugs. A generic drug is a medication that is bioequivalent to a brand-name drug in terms of dosage, safety, strength, quality, and intended use.
The ANDA submission process is a critical step in the drug development and approval process for generic drugs. It must establish that the proposed generic drug product meets all the same quality, safety, and efficacy standards as the brand-name product. In addition, the ANDA must show that the drug delivery system, dosage form, and labeling are similar to the brand-name product.
The ANDA process saves time and resources for manufacturers of generic drugs, as they do not need to demonstrate the safety and efficacy of the active ingredient or conduct clinical trials. Instead, they must show that their product is the bioequivalent of the brand-name product.
Once approved, generic drugs are typically less expensive than their brand-name counterparts, making them more accessible and affordable for patients. The availability of generic drugs also increases competition in the market, which helps to lower drug prices even further.
Overall, ANDA plays a crucial role in the healthcare industry by ensuring that patients have access to safe, effective, and affordable medications.
ANDA Abbreviated New Drug Application
Health Care Term
ANDA (Abbreviated New Drug Application) is a regulatory submission that pharmaceutical companies submit to the Food and Drug Administration (FDA) to seek approval to sell generic drugs. A generic drug is a medication that is bioequivalent to a brand-name drug in terms of dosage, safety, strength, quality, and intended use.
The ANDA submission process is a critical step in the drug development and approval process for generic drugs. It must establish that the proposed generic drug product meets all the same quality, safety, and efficacy standards as the brand-name product. In addition, the ANDA must show that the drug delivery system, dosage form, and labeling are similar to the brand-name product.
The ANDA process saves time and resources for manufacturers of generic drugs, as they do not need to demonstrate the safety and efficacy of the active ingredient or conduct clinical trials. Instead, they must show that their product is the bioequivalent of the brand-name product.
Once approved, generic drugs are typically less expensive than their brand-name counterparts, making them more accessible and affordable for patients. The availability of generic drugs also increases competition in the market, which helps to lower drug prices even further.
Overall, ANDA plays a crucial role in the healthcare industry by ensuring that patients have access to safe, effective, and affordable medications.